Reflex testing for anti-HDV in HBsAg-positive patients offers high diagnostic yield in a large Central European tertiary care center.
Humans
Hepatitis B Surface Antigens
/ blood
Female
Male
Middle Aged
Tertiary Care Centers
Hepatitis Delta Virus
/ immunology
Hepatitis D
/ diagnosis
Retrospective Studies
Aged
Adult
Hepatitis B
/ epidemiology
Seroepidemiologic Studies
Coinfection
/ diagnosis
Mass Screening
/ methods
Hepatitis Antibodies
/ blood
Hepatitis B virus
/ immunology
Antivirals
Epidemiology
Hepatitis delta
Hepatology
Virology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
28
02
2024
accepted:
24
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Current guidelines recommend reflex testing for hepatitis D virus (HDV) coinfection in hepatitis B surface antigen (HBsAg)-positive patients over risk-factor based screening. We aimed to evaluate the feasibility and diagnostic yield of reflex anti-HDV testing at a Central European tertiary care center. We retrospectively included 560 consecutive patients who had a recorded (first) positive HBsAg test result at the Vienna General Hospital between 2018 and 2022. While reflex anti-HDV testing had been implemented in our hepatitis outpatient clinic (n = 153, 'reflex testing cohort'), HDV screening needed to be manually ordered in the remaining patients (n = 407, 'standard testing cohort'). Overall, 98.0% and 65.1% of patients in the reflex and standard testing cohort were screened for anti-HDV, respectively, and the overall seroprevalence of anti-HDV among screened patients was 6.7% (n = 28, reflex testing cohort: 9.3%, standard testing cohort: 5.3%). Risk factors for HDV were present in 49.1% of all included and in 89.3% of anti-HDV positive patients, respectively. Anti-HDV positive patients showed higher ALT (54 [33-83] vs. 29 [19-49] U/L; p = 0.005) and a higher proportion of low-to-undetectable HBV-DNA (61.5% vs. 33.2%; p < 0.001), as compared to anti-HDV negative patients. HDV-RNA PCR was ordered in n = 21/28 (75.0%) of anti-HDV positive patients, and 76.2% had detectable HDV-RNA. Among viremic patients, 75% and 37.5% had significant fibrosis (≥ F2) or cirrhosis (F4), respectively. The prevalence of anti-HDV among HBsAg-positive patients is considerable in a large hospital located in Central Europe. Double reflex testing, i.e., anti-HDV being triggered by the presence of HBsAg and HDV-PCR bring triggered by the presence of anti-HDV, seems warranted to increase the diagnostic yield.
Identifiants
pubmed: 39472518
doi: 10.1038/s41598-024-77737-4
pii: 10.1038/s41598-024-77737-4
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25921Informations de copyright
© 2024. The Author(s).
Références
Asselah, T. & Rizzetto, M. Hepatitis D Virus Infection. N. Engl. J. Med. 389, 58–70 (2023).
doi: 10.1056/NEJMra2212151
pubmed: 37407002
Miao, Z. et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J. Infect. Dis. 221, 1677–1687 (2020).
doi: 10.1093/infdis/jiz633
pubmed: 31778167
Stockdale, A. J. et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J. Hepatol. 73, 523–532 (2020).
doi: 10.1016/j.jhep.2020.04.008
pubmed: 32335166
pmcid: 7438974
Kamal, H. et al. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology 72, 1177–1190 (2020).
doi: 10.1002/hep.31214
pubmed: 32145073
Jachs, M. et al. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United Eur. Gastroenterol. J. 9, 1119–1127 (2021).
doi: 10.1002/ueg2.12163
EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017(67), 370–398 (2017).
EASL Clinical Practice Guidelines on hepatitis delta virus. J. Hepatol. 79, 433–460 (2023).
doi: 10.1016/j.jhep.2023.05.001
Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018).
doi: 10.1002/hep.29800
pubmed: 29405329
Palom, A. et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep. 4, 100547 (2022).
doi: 10.1016/j.jhepr.2022.100547
pubmed: 36052219
pmcid: 9425021
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659–689 (2021).
Jachs, M. et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a “real world” study. Aliment Pharmacol. Ther. 56, 144–154 (2022).
doi: 10.1111/apt.16945
pubmed: 35514008
pmcid: 9321570
Jachs, M. et al. Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United Eur. Gastroenterol. J. 11, 293–304 (2023).
doi: 10.1002/ueg2.12376
Cossiga, V. et al. Anti-HDV reflex testing in HBsAg-positive subjects: An efficacious strategy to identify HDV infection. Liver Int. 44, 148–154 (2024).
doi: 10.1111/liv.15746
pubmed: 37789576
Razavi, H. A. et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J. Hepatol. 79, 576–580 (2023).
doi: 10.1016/j.jhep.2023.02.041
pubmed: 37030400